Clinical trials: Active Refractory Rheumatoid Arthritis
Active Rheumatoid Arthritis
Pulse Steroid Injection in Refractory Rheumatoid Arthritis
Remission or low disease activity in active rheumatoid arthritis
- Trial name
- NCT06456489
- Testing
- Solumedrol
- Where
- Egypt
- Volunteers
- 268 people
- Sponsor
- Sohag University
Rheumatoid Arthritis
Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis
The goal of this phase I/II clinical trial is to compare B-cell depletion by rituximab and anti-CD 19 CAR-T therapy in patients with rheumatoid arthritis.
- Trial name
- COMPARE (NCT06475495)
- Testing
- KYV101, Rituximab (active comparator)
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Charite University, Berlin, Germany
Rheumatoid Arthritis
Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT05460832
- Testing
- MBS2320 5 mg, MBS2320 20 mg, MBS2320 40 mg
- Where
- 46 sites in Bosnia and Herzegovina, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Modern Biosciences Ltd
Rheumatoid Arthritis
GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis
Part A: 30 patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will receive once daily two capsules containing either GLPG0259 (25 mg/capsule) or matching placebo, for 12 weeks.
- Trial name
- NCT01211249
- Testing
- GLPG0259 oral capsule, GLPG0259 (Part B)
- Where
- 32 sites in Belgium, Netherlands and 3 more
- Volunteers
- 30 people
- Sponsor
- Lakefront Biotherapeutics NV
Rheumatoid Arthritis
Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
Thirty six patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 or matching placebo for 4 weeks.
- Trial name
- NCT01384422
- Testing
- GLPG0634
- Where
- Moldova
- Volunteers
- 36 people
- Sponsor
- Lakefront Biotherapeutics NV
Rheumatoid Arthritis
Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
Ninety patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 (4 different doses will be evaluated) or matching…
- Trial name
- NCT01668641
- Testing
- GLPG0634
- Where
- 19 sites in Hungary, Moldova and 2 more
- Volunteers
- 91 people
- Sponsor
- Lakefront Biotherapeutics NV
Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and…
- Trial name
- NCT06570798
- Testing
- Inebilizumab, Blinatumomab
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 220 people
- Sponsor
- Amgen
Rheumatoid Arthritis (RA)
The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Trial name
- NCT07001956
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rheumatoid Arthritis (RA)
Masitinib in Refractory Active Rheumatoid Arthritis
The objective is to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1.
- Trial name
- NCT01410695
- Testing
- masitinib 3 mg, masitinib 6.0 mg, methotrexate
- Where
- Czechia
- Volunteers
- 324 people
- Sponsor
- AB Science
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
The purpose of this study is to evaluate the safety and efficacy of sirukumab as a single therapy in Japanese patients with moderately to severely active rheumatoid arthritis (RA) who have not responded to treatment with…
- Trial name
- NCT01689532
- Testing
- Sirukumab 100 mg, Sirukumab 50 mg
- Where
- 17 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Janssen Pharmaceutical K.K.
Rheumatoid Arthritis (RA)
An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis
The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.
- Trial name
- NCT06946199
- Testing
- Cizutamig
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rheumatoid Arthritis
Faecal Microbiota Transplantation in Patients With Refractory Rheumatoid Arthritis
In this 24-week, single center, randomized, double-blind, placebo-controlled study, the efficacy and safety of lyophilised oral fecal microbiota transplantation in patients with active refractory rheumatoid arthritis will be…
- Trial name
- NCT07639177
- Testing
- lyophilised oral capsules with faecal microbiota
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Rheumatoid Arthritis (RA)
Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Trial name
- NCT06982547
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Rheumatoid Arthritis, Arthritis, Rheumatoid
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies.
- Conditions
- Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
- Trial name
- NCT06087406
- Testing
- Imvotamab
- Where
- 18 sites in United States, Poland
- Volunteers
- 33 people
- Sponsor
- IGM Biosciences, Inc.